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Abstract
Juvenile idiopathic arthritis (JIA) is the most common form of chronic rheumatic disease
affecting children worldwide, with some features similar to adult rheumatoid arthritis (RA). In
the present study, we aim at investigating novel markers that will allow in the future for
tailored, more personalized treatment strategies. Hence, taking notice of several reports
proving the role of local acidosis as a causal link between inflammatory diseases and related
pain, and the involvement of several carbonic anhydrases (CA, EC 4.2.1.1) isoforms in articular
diseases, we evaluated in JIA patients the expression of these metalloenzymes. We identified
that JIA patients show high levels of active CA IX and XII isoforms. Our results represent the first
evidence of the identification of these enzymes as potential therapeutic targets and
development of novel innovative therapies for arthritis, also considering that the two isoforms
are validated antitumor targets.
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Introduction
The synovial membrane may become inflamed and thickened in
conditions such as rheumatoid arthritis (RA) and juvenile
idiopathic arthritis (JIA), the latter been the most common
chronic rheumatic disease in the pediatric age. The pathophysi-
ology of JIA has been related to that of RA, which is
considered a chronic autoimmune disorder. Inflammatory cells
such as T lymphocytes produce cytokines that sustain the
process of synovial pannus-driven extracellular proteolysis and
proliferation, and promote the inflammation-associated angio-
genesis. Very old observations report high hydrogen ions
concentration in inflamed tissues and have highlighted the
importance of low pH of the synovial fluid of RA patients, thus
indicating that pH becomes more acidic as the intensity of the
inflammatory reaction increases1. Local acidosis has been
suggested to provide a causal link between inflammatory
diseases and their related pain2. Data also indirectly point to
low-pH-dependent reduction in the proliferation of lymphocytes
and polymorphs, impaired chemotaxis and inhibition of anti-
body production3.
Several forms of carbonic anhydrases (CAs, EC 4.2.1.1),
metalloenzymes that reversibly catalyze the conversion of CO2 to
the bicarbonate ions and protons4, have been recognized in
articular diseases, including CA I which is over-expressed in the
synovium of the patients with ankylosing spondylitis5. Transgenic
mice over-expressing CA I showed aggravated joint inflammation
and destruction6. CA I has been identified as an oral biomarker in
oral fluid of Sjogren’s syndrome7, and antibodies to CA III and IV
have been identified in rheumatoid arthritis8. In consideration of
the paucity of data on CAs in rheumatic diseases, we have studied
the presence of CA IX and XII, two emerging CAs which are
pivotal in many human pathologies4, in the synovial fluid and
synovial cells of JIA patients. Our results show a significant
increase of CA IX and CA XII protein and activity in biological
specimens from JIA patients.
Materials and methods
Sample preparation
Whole blood samples from healthy donors and from the patients
with JIA were collected by using EDTA, heparin and acid citrate
dextrose (ACD) as anticoagulants after informed consent and with
local Ethics Committee approval. The tubes were processed
immediately, or after overnight storage at 4 C. Samples were
prepared after diluting a 3 to 5 ml aliquot of blood 1:2 with
Millipore water (milliQ), mixed by vortex for 3 min and stored at
4 C for 24 h. The samples were thus centrifuged for 30 min at
6000 rpm at 4 C and the pellet was discarded. Samples of
synovial fluid, previously taken during therapeutic arthrocentesis
from patients with JIA, were stored at 18 C until analysis
(minimum an overnight). After thaw at room temperature,
samples were analyzed with the same protocol.
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Synovial samples
Synovial fibroblasts were derived from 7 JIA patients (mean age:
9 years, range: 9–15 years) and 6 healthy controls (mean age: 8
years, range: 5–10 years), after informed written consent and with
the approval of Ethics Committee of Anna Meyer Children
Hospital, Florence, Italy.
For patients under the age of 18 years, written consent was
obtained by the parents or guardians. All the procedures of this
study have been conducted according to the principles expressed
in the Declaration of Helsinki.
Healthy synovial tissue was removed from knee joints of
controls during orthopedic surgery for traumatic fractures or
elective procedures, minced into small pieces and plated in
culture dishes with FBM-2 (Fibroblast Growth Medium,
Microtech, Napoli, Italy) supplemented with 10% FBS for
expansion. JIA synovial fibroblasts were obtained from synovial
fluid of JIA patients, as previously described9.
CA concentration determination
The protein concentration in the samples was determined
spectrophotometrically by measuring the absorbance at 280 nm
using a molar extinction coefficient e¼ 50 070 M 1 cm 1
calculated using A280 (1%) of 19.0 according to Nyman and
Lindskog protocol10 and a molecular weight value of 30 kDa for
CA II, 59 kDA for CA IX and 54 kDA for CA XII (dimeric
enzymes)11,12. Absorption spectrophotometry was carried out
using a Cary 50 Conc UV/Visible spectrophotometer connected to
a Lauda A100 thermostatic water bath to maintain a constant
temperature in the cell holder.
CA IX and XII inhibition assay
The presence of active CA in the enzyme solutions freshly made
up from the lysed biological samples was determined by using a
stopped-flow assay. 0.1mM solution of the enzyme was obtained
by diluting determined amount of the blood/serum/synovial fluid/
synoviocytes samples (based on the protein content previously
determined by A280) in a buffer containing 10 mM Hepes (pH
7.4), 10 mM Tris.HCl and 0.1 M NaSO4. Phenol red (at a
concentration of 0.2 mM) was added to the enzyme solutions and
used as pH indicator. An applied photophysics stopped-flow
instrument has been used for assaying the CA catalyzed CO2
hydration activity (Leatherhead, Surrey, UK)13. Phenol red has
been used as indicator, working at the absorbance maximum of
557 nm, with 10 mM Hepes (pH 7.4), 10 mM Tris. HCl and 0.1 M
NaSO4 (for maintaining constant the ionic strength), following the
initial rates of the CA-catalyzed CO2 hydration reaction for a
period of 10–100 s. The CO2 concentrations ranged from 1.7 to
17 mM for the determination of the catalytic activity and
inhibition constants. The pan-inhibitor acetazolamide (AAZ)
and the CA IX/XII-selective Coumarin inhibitor C were used to
assess the inhibition of various CA isoforms. For each inhibitor, at
least six traces of the initial 5–10% of the reaction have been used
for determining the initial velocity. The uncatalyzed rates were
determined in the same manner and subtracted from the total
observed rates. Stock solutions of inhibitor (10 mM for AAZ or
C) were prepared in distilled-deionized water and dilutions up to
100 or 0.01 nM were done thereafter with distilled-deionized
water. Inhibitor and enzyme solutions were pre-incubated together
for 15 min at room temperature prior to assay, in order to allow for
the formation of the E-I complex. The inhibition constants were
obtained by non-linear least-squares methods using PRISM 3. The
kinetic parameters for the uninhibited enzymes were derived from
Lineweaver–Burk plots, as reported earlier4,14,15, and represent
the mean from at least three different determinations.
Quantitative real-time PCR
Total RNA was prepared using Nucleospin RNA II (Macherey-
Nagel, Carlo Erba Reagents, Milano, Italy), agarose gel was
checked for integrity, and reverse transcribed with GoScript
system (Promega, Madison, WI) using random primers according
to manufacturer’s instructions. CA IX and CA XII expression in
normal SFs under various conditions was determined by a
quantitative Real-Time (RT)–PCR with an Applied Biosystem
7500 Fast Real Time PCR System (Applied Biosystems,
Carlsbad, CA) and determined by the comparative Ct method
using 18S ribosomal RNA as the normalization gene.
Amplification was performed with the default PCR setting: 40
cycles of 95 C for 15 s and of 60 C for 60 seconds using SYBR
Green–based detection (GoTaq qPCR Master Mix; Promega,
Madison, WI). Primers (IDT, TemaRicerca) used for RT-PCR
were as follows:
18S-rRNA sense 50-CCAGTAAGTGCGGGTCATAAG-30,
antisense 50-GCCTCACATA-ACCATCCAATC-30; CAIX
sense 50-GGAAGGCTCAGAGACTCA-30, antisense 50-CTTAG-
CACTCCAGCAGTCAC-30; CAXII sense 50-CTGCCAGCAAC
AAGTCCAG-30, antisense 50-ATATTCAGCGGTCCTCTC-30.
Western blotting
Aliquots of lysates (30mg) of normal and JIA synovial fibroblasts
were subjected to SDS-polyacrylamide gel electrophoresis
(PAGE) and Western blotting. Membranes were probed with
primary antibodies against: CAIX and CAXII (Sigma-Aldrich, St.
Louis, MO), while tubulin (Sigma-Aldrich, St. Louis, MO) was
used as loading control. Suitable peroxidase-conjugated IgG
preparations (Sigma-Aldrich, St. Louis, MO) have been used as
secondary antibodies; the ECL procedure was employed for
development.
Results and discussion
The total CA activity was measured in whole blood, serum,
synovial fluid (only in patients) and synoviocytes from healthy
donors (n¼ 5) and JIA patients (n¼ 14) by using a CO2hydrase
stopped-flow technique (Table 1). The pan-CA inhibitor AAZ as
well as the isoform-selective Coumarin inhibitor C (which does
not inhibit the cytosolic, red blood cell isoforms CAI and II, but
selectively inhibits in the low nM range the transmembrane
isoforms CA IX and XII) were also used in these experiments in
Table 1. Levels of carbonic anhydrase present in the lysed samples of
blood, serum, synovial fluid and synoviocytes (from healthy controls or
JIA patients) and inhibition data with the standard sulfonamide inhibitor
acetazolamide (AAZ) and CA IX/CA XII-selective Coumarin inhibitor C
(Figure 1) by a stopped flow CO2 hydrase assay.
Sample % CA activity
Healthy donors JIA patients
Blood 100 ± 3.9 100 ± 6.2
Serum 100 ± 5.1 100 ± 4.8
Synovial fluid NO 135.4 ± 12
Synoviocytes 100 ± 4.7 129.2 ± 8.1
Blood +AAZ, 10 mM 6.8 ± 0.2 5.9 ± 0.5
Serum +AAZ, 10 mM 6.3 ± 0.5 6.1 ± 0.4
Synovial fluid +AAZ, 10mM NO 5.5 ± 0.2
Synoviocytes +AAZ, 10mM 6.0 ± 4.2 5.9 ± 0.7
Blood + Coumarin C, 10mM 100 ± 5.1 100 ± 4.5
Serum +C, 10 mM 100 ± 3.9 100 ± 4.5
Synovial fluid +C, 10mM NO 25.8 ± 3.4
Synoviocytes +C, 10mM 16.0 ± 33.8 23.4 ± 2.3
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order to try to recognize the contribute of various CA isoforms to
the measured activity.
As seen from the data of Table 1, the CA activity in blood and
serum was identical (within the limits of the experimental error)
in the samples from healthy subjects and JIA patients, whereas the
synovioctyes had an increased total CA activity of 129.2%, in
patients compared controls. We have also investigated the
response of the samples to inhibition with AAZ (a compound
inhibiting all CA isoforms) and Coumarin C, which is a CA IX/
XII selective inhibitor (not inhibiting the cytosolic CA I and II,
Figure 1).
As seen in Table 1, AAZ (at 10 mM) totally inhibited the CA
activity in all samples, as expected, since this compound has a
good affinity for all CAs, the widespread (in blood) isoforms CA I
and II, as well as for transmembrane isoforms (which are normally
absent from blood/plasma). There were no significant differences
between patients and controls in their response to AAZ inhibition.
Coumarin C on the other hand showed no inhibitory effects
against blood and serum samples (both in healthy subjects and in
patients), as expected, since there should be no transmembrane
CA isoforms in these fluids. However, a strong inhibitory effect of
Figure 3. Western blotting detection of CA IX and CA XII in synovial fibroblasts from healthy donors and from JIA patients. Tubulin expression and
Ponceau staining are used as a control for protein loading. Histograms on the right report band densitometry.
Figure 2. The CA IX and CA XII mRNA expression levels were quantified in healthy and JIA synovial fibroblasts using real time-PCR. 18s was used
as housekeeping gene. Results of three independent experiments performed in triplicates are expressed as fold change according to 2DDCT method.
Figure 1. The pan-inhibitor of CAs acetazolamide (AAZ) and its
inhibition constants against isoforms CA I, II, IX and XII, and the
newly developed, isoform-selective Coumarin inhibitor C, and its
inhibitory activity against the same isoforms.
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the CA activity from the synovial fluid, and from synoviocytes of
both healthy subjects and patients has been observed, which is
indicative of the presence of CA IX and XII in SF and
synoviocytes. This is the first report for the presence of isoforms
normally associated with tumors in these tissues/fluids. It should
be however mentioned that both CA IX and XII are also found in
some normal tissues, such as body lining and stomach (CA IX)
and kidneys, brain and ciliary processes of the eye (CA XII).
To investigate whether the increased activity of CA IX and CA
XII was due to an increase of the two enzymes at mRNA and protein
levels, real time-PCR and Western blot analysis were performed
(Figures 2 and 3) on healthy and JIA synovial fibroblasts. The data
show that JIA fibroblasts displayed higher CA XII mRNA levels
compared with synovial fibroblasts from healthy donors, while CA
IX expression was found surprisingly higher in the latter. However,
Western blot analysis showed an increase of both CA XII (8-fold
higher) and CA IX protein levels in JIA synovial fibroblasts. This
may be due to some hypoxia that is probably present in these
compartments, and as well known, hypoxia triggers over-expression
of CA IX (and sometimes also CA XII) through the hypoxia-
inducible factor 1a (HIF-1a) pathway4.
To our knowledge this is the first report on CA IX and XII
overexpression in the inflamed synovium. Indeed, these findings
may have a translational relevance, since beside the current use of
CA inhibitors for the treatment of various pathologies such as
tumors, obesity, epilepsy, they may be of critical importance for
the development of novel therapeutic strategies for arthritis.
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